Literature DB >> 31843680

Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy?

Michael P Whyte1, S Deepak Amalnath2, William H McAlister3, Marc D McKee4, Deborah J Veis5, Margaret Huskey6, Shenghui Duan7, Vinieth N Bijanki8, Suhas Alur2, Steven Mumm9.   

Abstract

The SIBLINGs are a subfamily of the secreted calcium-binding phosphoproteins and comprise five small integrin-binding ligand N-linked glycoproteins [dentin matrix protein-1 (DMP1), secreted phosphoprotein-1 (SPP1) also called osteopontin (OPN), integrin-binding sialoprotein (IBSP) also called bone sialoprotein (BSP), matrix extracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein (DSPP)]. Each SIBLING has at least one "acidic, serine- and aspartic acid-rich motif" (ASARM) and multiple Ser-x-Glu/pSer sequences that when phosphorylated promote binding of the protein to hydroxyapatite for regulation of biomineralization. Mendelian disorders from loss-of-function mutation(s) of the genes that encode the SIBLINGs thus far involve DSPP causing various autosomal dominant dysplasias of dentin but without skeletal disease, and DMP1 causing autosomal recessive hypophosphatemic rickets, type 1 (ARHR1). No diseases have been reported from gain-of-function mutation(s) of DSPP or DMP1 or from alterations of SPP1, IBSP, or MEPE. Herein, we describe severe hypophosphatemic osteosclerosis and hyperostosis associated with skeletal deformity, short stature, enthesopathy, tooth loss, and high circulating FGF23 levels in a middle-aged man and young woman from an endogamous family living in southern India. Both shared novel homozygous mutations within two genes that encode a SIBLING protein: stop-gain ("nonsense") DMP1 (c.556G>T,p.Glu186Ter) and missense SPP1 (c.769C>T,p.Leu266Phe). The man alone also carried novel heterozygous missense variants within two additional genes that condition mineral homeostasis and are the basis for autosomal recessive disorders: CYP27B1 underlying vitamin D dependent rickets, type 1, and ABCC6 underlying both generalized arterial calcification of infancy, type 2 and pseudoxanthoma elasticum (PXE). By immunochemistry, his bone contained high amounts of OPN, particularly striking surrounding osteocytes. We review how our patients' disorder may represent the first digenic SIBLING protein osteopathy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCC6; Autosomal recessive hypophosphatemic rickets; Burosumab; CYP27B1; Endogamy; FGF23; Heterotopic ossification; Hydroxyapatite; Hypophosphatemia; Inorganic phosphate; Iron deficiency; Mineralization; Osteomalacia; Phosphatonin; Rickets; Scoliosis; Tooth loss

Mesh:

Substances:

Year:  2019        PMID: 31843680      PMCID: PMC7271119          DOI: 10.1016/j.bone.2019.115190

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  42 in total

1.  Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin.

Authors:  Betty Hoac; Valentin Nelea; Wenge Jiang; Mari T Kaartinen; Marc D McKee
Journal:  Bone       Date:  2017-04-18       Impact factor: 4.398

2.  Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring.

Authors:  D W Sherer; L Bercovitch; M Lebwohl
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

3.  Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone.

Authors:  Betty Hoac; Delia Susan-Resiga; Rachid Essalmani; Edwige Marcinkiweicz; Nabil G Seidah; Marc D McKee
Journal:  Bone       Date:  2017-11-07       Impact factor: 4.398

4.  A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets.

Authors:  Ryusuke Koshida; Hideki Yamaguchi; Koji Yamasaki; Wakaba Tsuchimochi; Tadato Yonekawa; Masamitsu Nakazato
Journal:  J Bone Miner Metab       Date:  2010-03-09       Impact factor: 2.626

5.  Pseudoxanthoma elasticum: a metabolic disease?

Authors:  Qiujie Jiang; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2006-07       Impact factor: 8.551

6.  Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia.

Authors:  Tchilalo Boukpessi; Betty Hoac; Benjamin R Coyac; Thibaut Leger; Camille Garcia; Philippe Wicart; Michael P Whyte; Francis H Glorieux; Agnès Linglart; Catherine Chaussain; Marc D McKee
Journal:  Bone       Date:  2016-11-21       Impact factor: 4.398

7.  Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.

Authors:  Jian Q Feng; Leanne M Ward; Shiguang Liu; Yongbo Lu; Yixia Xie; Baozhi Yuan; Xijie Yu; Frank Rauch; Siobhan I Davis; Shubin Zhang; Hector Rios; Marc K Drezner; L Darryl Quarles; Lynda F Bonewald; Kenneth E White
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

8.  DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.

Authors:  Bettina Lorenz-Depiereux; Murat Bastepe; Anna Benet-Pagès; Mustapha Amyere; Janine Wagenstaller; Ursula Müller-Barth; Klaus Badenhoop; Stephanie M Kaiser; Roger S Rittmaster; Alan H Shlossberg; José L Olivares; César Loris; Feliciano J Ramos; Francis Glorieux; Miikka Vikkula; Harald Jüppner; Tim M Strom
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

9.  Compound heterozygosity for a recurrent 16.5-kb Alu-mediated deletion mutation and single-base-pair substitutions in the ABCC6 gene results in pseudoxanthoma elasticum.

Authors:  F Ringpfeil; A Nakano; J Uitto; L Pulkkinen
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

10.  Phosphorylation of Extracellular Bone Matrix Proteins and Its Contribution to Bone Fragility.

Authors:  Grażyna E Sroga; Deepak Vashishth
Journal:  J Bone Miner Res       Date:  2018-08-07       Impact factor: 6.741

View more
  4 in total

Review 1.  Role of Phosphate in Biomineralization.

Authors:  Sanjay Kumar Bhadada; Sudhaker D Rao
Journal:  Calcif Tissue Int       Date:  2020-07-25       Impact factor: 4.333

2.  Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.

Authors:  Svetlana Katchkovsky; Biplab Chatterjee; Chen-Viki Abramovitch-Dahan; Niv Papo; Noam Levaot
Journal:  Cell Mol Life Sci       Date:  2022-01-31       Impact factor: 9.261

Review 3.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

4.  A transcriptomics-guided drug target discovery strategy identifies receptor ligands for lung regeneration.

Authors:  Xinhui Wu; I Sophie T Bos; Thomas M Conlon; Meshal Ansari; Vicky Verschut; Luke van der Koog; Lars A Verkleij; Angela D'Ambrosi; Aleksey Matveyenko; Herbert B Schiller; Melanie Königshoff; Martina Schmidt; Loes E M Kistemaker; Ali Önder Yildirim; Reinoud Gosens
Journal:  Sci Adv       Date:  2022-03-23       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.